Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al., ex rel. Christina Lemons v. Reckitt Benckiser Group PLC, Inc., et al.
Case Number:
1:15-cv-00016
Court:
Nature of Suit:
Other Statutes: False Claims Act
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
May 13, 2021
Indivior Wants Ex-Worker's Retaliation Claims Thrown Out
Pharmaceutical manufacturer Indivior said that a former employee's False Claims Act retaliation claims should be axed, calling her case "the latest in a long line of attempts … to cash in on her departure."
-
April 27, 2021
Indivior Finalizes $300M Deal To End Suboxone Cases
Pharmaceutical manufacturer Indivior has finalized an agreement to pay a total of $300 million to all 50 states to settle allegations it falsely and aggressively marketed the opioid-based drug Suboxone, an alleged scheme that led to the misuse of Medicaid funds, according to a settlement released by the California Attorney General's office Tuesday.
-
July 12, 2019
How A Doc's FCA Suit Turned Into $1.4B Opioid Deal
An addiction specialist looking to take on Reckitt Benckiser's marketing practices for its opioid treatment found a path to victory by filing a whistleblower suit so that the federal government would get involved, culminating in a record-breaking $1.4 billion deal.